Latest issue now available. Join thousands of subscribers who have discovered the convenience of our free monthly publication, by signing up today. https://ow.ly/hTYQ50Zu7sT Compiled and collated by ICON’s Regulatory I...
Designing the future
Regulatory readiness for next-generation AI-enabled software as a medical device (SaMD)
Read the whitepaperFrom here to where?
Plotting a course to bring APAC-developed drugs to the world
Read the whitepaperGlobal regulatory strategies for immunology
Success factors for hypercompetitive therapy
Read the whitepaper
Featured solutions
Orbis
ICON’s multi-agent platform that connects human expertise, data and AI across the clinical trial lifecycle.
EngageAI
Our voice of the customer feedback platform has been enhanced using AI; transforming how we listen, respond, and act on your feedback.
Blended solutions
Bespoke, seamless solutions to meet unique sponsor challenges.
Manufacturing & Pharmacy Services
Rapid small batch formulation, manufacturing, labelling and distribution for clinical trials.
Outcome Measures
A multi-faceted approach to identifying, selecting, and implementing evidence-based measures that matter to patients.
Biotech
ICON provides full service outsourcing and flexible support for biotech specific needs such as due diligence and asset valuation.
Cardiac Safety Solutions
End-to-end cardiac safety solutions, including ECG, event monitoring, BPM, long-term Holter monitoring, ECHO and MUGA studies.
Early Clinical and Bioanalytical Solutions
Innovative early clinical solutions that will advance your drug development strategy.
Site & Patient Solutions
Transforming recruitment through patient-centric trials and real-world, real-time data.
Market Access
Expertise in mission-critical pricing, market access, and reimbursement.
Specialty Laboratory Solutions
Supporting precision medicine programs across all phases of drug diagnostic co-development.
Webinars
Insights into first-in-human study design of oligonucleotides
Watch the webinar.
When patients lead: Breaking barriers in ultra-rare disease drug development
Watch the webinar.
ICH GCP E6(R3): Preparing for global implementation, assessing the impact, risk and requirements of the change
Watch the webinar.